证券研究报告 | 行业定期报告 2025 年 07 月 13 日 继续推荐 RWA&稳定币主线，关注 RDA 投资机会 计算机周观察 20250713 TMT 及中小盘/计算机 7 月 10 日，上海国资委组织学习加密货币与稳定币，国家金融改革实验室讨论 在上海自贸区试点推动人民币稳定币。RDA 作为锚定数据资产的 RWA，近期 关注度提升，建议持续关注稳定币&RWA 核心标的及数据要素厂商投资机会。 ❑ 风险提示：相关政策不及预期风险；行业竞争加剧风险。 推荐（维持） 2、《海外推出股票 RWA，国内无人 物流产业深化 ——计算机周观察 20250706》2025-07-06 3、《AI 及无人化聚焦落地，重视稳 定币及 RWA 金融创新——计算机行 业 2025 年 中 期 投 资 策 略 》 2025-06-30 刘玉萍 S1090518120002 liuyuping@cmschina.com.cn 孟林 S1090521040001 menglin@cmschina.com.cn 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 284 | 5.6 | ...

2025 年 07 月 13 日 计算机 RDA：链接加密货币和数据要素的桥梁 7 月 10 日，上海市国资委党委召开中心组学习会，围绕加密货币与 稳定币的发展趋势及应对策略开展学习。此前 7 月 2 日，上海数据交 易交所在财政部主管的中央级财经媒体发表署名文章《RDA：数据要 素价值化探索》，首次提出 RDA（Real Data Assets）新范式，以期 构建链接加密货币和数据要素的桥梁。 证券研究报告 投资评级 领先大市-A 维持评级 RDA：实数融合新范式、数据价值化新引擎 RWA（Real Word Assets）作为资产价值化新赛道，具有经济性、共 识性、真实性、流动性、透明性五大优势，在全球范围内发展迅速， 促进了实体资产在数字世界的价值映射。上海数据交易所首次提出 RDA （Real Data Assets）新范式，更强调锚定实数融合的实体资产， 更强调数据对其他实体资产的真实性校验和价值提升等作用，RDA 一 方面可以帮助数据要素市场化、价值化进程加速，另一方面可以推动 数据要素和其他要素的联动发展，提升实体资产和资本的对接效率， 促进新质生产力发展，推动实体经济和数字经济深度融合制度落地 ...

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

[Table_Title] 证券研究报告 / 行业动态报告 AI 25H2（3）：数据为先，RDA 推动实数融合 事件： [Table_Summary] 国家金融与发展实验室副主任杨涛表示，基于 Web3.0 世界打造的稳定 币已经超越了传统的离岸与在岸范畴，为了更好地实现战略统筹、主动 监管、协同推进，应该考虑采取境内离岸与境外离岸人民币稳定币的联 动发展模式。 点评： ➢ 人民币稳定币呈现"内外结合"趋势 相关标的： 数据资产：上海钢联、道通科技、普联软件、找钢集团、慧辰股份、数 字政通、久远银海； 链上交易：宇信科技、新国都、四方精创、连连数字、众安在线。 （注：以上公司除数字政通外，其余尚未有研报覆盖，且仅为有限列示 相关的公司，不作为投资推荐。） 风险提示：政策进展不及预期；下游需求不及预期。 执业证书编号：S0550525050001 zhaoyy1@nesc.cn [Table_Info1] 计算机 [Table_Date] 发布时间：2025-07-12 [Table_Invest] 优于大势 上次评级:优于大势 1）境外离岸人民币业务是指在境外市场开展以人民币计价结算的金融业 务，在政策驱动 ...

部分 第 01 行情回顾 02 板块观点和投资组合 03 行业和个股事件 本周行情回顾 =半创研究 本周中信一级行业指数涨跌幅 本周涨幅排名前/后十名的股票 ST未名 -18.51 前沿生物-U 41.43% 7% -13.36% 神州细胞 美迪西 38.92% 6% 舒泰伸 联环药业 38.58% -11.61% 5%6 一品红 康辰药业 27.28% 4%6 海辰药业 启迪药业 26.89% 3% 华海药业 2% 华纳药厂 24.44% 1% 美诺华 浩欧博 22.72% os 永安药业 塞力医疗 22.06% 新闻 48 14 18 1987 1989 荣昌生物 福瑞股份 20.83% 8.84% 创新医疗 20.76% 广生堂 -8.66% 30% -10% -596 -15% 10% 证监会审核华创证券投资咨询业务资格批文号:证监许可(2009) 1210 号 第二部分 01 行情回顾 板块观点和投资组合 02 03 行业和个股事件 整体观点和投资主线 =半创研究 · 整体观点：当前医药板块的估值处于低位，公募基金（剔除医药基金）对医药板块的配置处于低位，考虑到美债利率等宏观环境 因素的积极恢复、大 ...

Core Points - Livingston has met its affordable housing quota for the next decade, with over nine years to spare, according to town officials [3][15][20] - The township's Fourth Round Housing Element and Fair Share Plan has been officially endorsed by the Livingston Township Council [4][19] Group 1: Housing Quota and Planning - The initial affordable housing requirement for Livingston was set at 461 units, which was later reduced to 430 units through a settlement [9][8] - A "Vacant Land Adjustment" (VLA) was applied, reducing the Realistic Development Potential (RDP) to only 13 units due to a lack of available land for new development [10][11] - The total obligation for the Fourth Round was calculated to be 94 units, which includes the RDP and 25% of the remaining adjusted prospective need [12][18] Group 2: Compliance and Future Planning - Livingston has already satisfied its Fourth Round obligation through strategic planning and the use of surplus credits from previous rounds [15][16] - The township has banked an additional 78.5 credits from Fourth Round projects, along with 31 surplus credits from the Third Round, to address future obligations [18][20] - No additional new projects are required until 2035, as the township has met its obligations with already approved projects [19][20] Group 3: Legal and Regulatory Framework - The new state law mandates that municipalities must satisfy their RDP through approved zoning, which Livingston has complied with [11][21] - The township is prepared to defend its Housing Element and Fair Share Plan against potential objections, particularly from the New Jersey Builders Association [21][22] - Upon resolution of any objections, the plan will be eligible for compliance certification, providing legal protection against builder's remedy lawsuits through 2035 [23]

Core Insights - Merck (MRK) has announced a definitive agreement to acquire Verona Pharma (VRNA) for approximately $10 billion, which will enhance its cardio-pulmonary pipeline with the addition of Ohtuvayre, a drug approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) [1][10] - Ohtuvayre's unique dual inhibition of PDE3 and PDE4 distinguishes it from existing COPD treatments, combining bronchodilation and anti-inflammatory effects in a single inhaled therapy [2][10] - The acquisition is part of Merck's strategy to diversify its business as it faces the upcoming patent loss of its blockbuster drug Keytruda, which currently accounts for around 50% of the company's pharmaceutical sales [3][4][12] Merck's Product Portfolio and Pipeline - Keytruda remains Merck's biggest strength, driving steady revenue growth, particularly in early-stage non-small cell lung cancer [4][5] - Merck is exploring innovative combinations and developing a subcutaneous formulation of Keytruda to extend its patent life, with an FDA decision expected in September [6][7] - The company's phase III pipeline has nearly tripled since 2021, positioning it to launch around 20 new vaccines and drugs, including the promising Capvaxive and Winrevair [8][9] Challenges and Market Dynamics - Merck's reliance on Keytruda raises concerns about its ability to grow its non-oncology business ahead of the drug's loss of exclusivity in 2028 [12] - Competitive pressure is increasing, with potential challengers like Summit Therapeutics' ivonescimab showing promising results in clinical studies [13] - Sales of Gardasil, Merck's second-largest product, are declining in China due to weak demand, leading to a temporary halt in shipments [14][15] Financial Performance and Valuation - Merck's shares have underperformed the industry and the S&P 500, losing 14.0% so far this year [16][17] - The company's price/earnings ratio is currently at 8.99, lower than the industry average of 15.16, indicating potential attractiveness from a valuation standpoint [19] - EPS estimates for 2025 and 2026 have declined over the past 60 days, reflecting analysts' pessimistic outlook [22][24] Future Outlook - Despite current challenges, Merck's strong fundamentals and promising pipeline, along with the potential revenue from new products, suggest that long-term investors may find value in the stock [25][27] - The acquisition of Verona Pharma is expected to help fill the revenue gap created by Keytruda's upcoming loss of exclusivity, with Ohtuvayre already showing strong sales growth [26]

Group 1 - The article highlights a new wave of tariffs initiated by U.S. President Donald Trump, causing volatility in the U.S. stock market while Bitcoin is preparing for a new upward trend, breaking above $118,000 for the first time in two months [1] - The cryptocurrency market is experiencing broad gains, with Ethereum and Cardano also seeing significant increases, indicating a positive shift in the market [1] - There are signs of renewed interest in cryptocurrency ETFs, with substantial inflows reported, and the U.S. Congress designating the upcoming week as "Cryptocurrency Week," further supporting the bullish sentiment [1][2] Group 2 - Bitcoin's price surged by 4.6% to just below $119,000, while Ethereum surpassed $3,000 for the first time since February, reflecting strong investor interest [2] - The Bitcoin and Ethereum ETFs recorded their second-largest single-day inflow, indicating a growing appetite for these digital assets among institutional investors [3]

Core Points - The FDA has accepted Milestone Pharmaceuticals' response to the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, with a new PDUFA target action date set for December 13, 2025 [1][5] - Milestone has extended its $75 million Royalty Purchase Agreement with RTW Investments until December 31, 2025, to support the planned launch of CARDAMYST following FDA approval [2][4] FDA Review and Response - The FDA's acceptance of the response to the CRL is a significant milestone for CARDAMYST, and the company is optimistic about a potential approval decision later this year [3] - Milestone's response to the CRL included results from additional in-vitro studies and a plan to transfer manufacturing duties to vendors with recent FDA inspection history [5][6] Royalty Purchase Agreement - The Royalty Purchase Agreement allows RTW to purchase tiered royalty payments on etripamil's annual net product sales in exchange for a $75 million purchase price, contingent on FDA approval by December 31, 2025 [4] - The amendment to the agreement reflects RTW's ongoing commitment to Milestone and provides a future funding source for the company [2][3] Product Overview - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration to treat paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular response (AFib-RVR) [7][9] - If approved, CARDAMYST™ aims to offer a new treatment option for patients, allowing for on-demand care and self-management [7][9] Clinical Development - Etripamil has completed a Phase 3 clinical program for PSVT and a Phase 2 trial for AFib-RVR, indicating a robust clinical development pathway [8]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].